RightFit Trial Directory

Leukemia clinical trials in St Louis, MO

24 recruiting leukemia studies with a site in St Louis, MO.

All trials in St Louis, MO · All Leukemia trials

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Ballwin, MO · Bolivar, MO · Branson, MO · +452 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Kansas City, MO · St Louis, MO · +112 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

City of Saint Peters, MO · Creve Coeur, MO · St Louis, MO · +172 more sites

RecruitingPhase 1NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Sponsor: National Cancer Institute (NCI)

City of Saint Peters, MO · Creve Coeur, MO · St Louis, MO · +16 more sites

RecruitingPhase 1NCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

St Louis, MO · +6 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

City of Saint Peters, MO · Creve Coeur, MO · St Louis, MO · +222 more sites

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

St Louis, MO · +21 more sites

RecruitingPhase not listedNCT07313592

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

Sponsor: Washington University School of Medicine

St Louis, MO

RecruitingPhase not listedNCT07143669

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Sponsor: Blueprint Medicines Corporation

St Louis, MO · +24 more sites

RecruitingPhase 2 / Phase 3NCT07581002

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Sponsor: AbbVie

St Louis, MO · +5 more sites

RecruitingPhase 2NCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Sponsor: Allotera Therapeutics

St Louis, MO · +15 more sites

RecruitingPhase 3NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Sponsor: Janssen Research & Development, LLC

St Louis, MO · +58 more sites

RecruitingPhase 3NCT04293562

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Sponsor: Children's Oncology Group

Columbia, MO · Kansas City, MO · St Louis, MO · +183 more sites

RecruitingPhase 2 / Phase 3NCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Sponsor: Beat AML, LLC

St Louis, MO · +29 more sites

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Columbia, MO · Kansas City, MO · St Louis, MO · +161 more sites

RecruitingPhase not listedNCT05702645

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Sponsor: Children's Oncology Group

Kansas City, MO · St Louis, MO · +70 more sites

RecruitingPhase 1NCT06247787

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Sponsor: Children's Oncology Group

St Louis, MO · +18 more sites

RecruitingPhase 1NCT06001788

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Kura Oncology, Inc.

St Louis, MO · +37 more sites

RecruitingPhase not listedNCT05865301

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Sponsor: Stanford University

St Louis, MO · +21 more sites

RecruitingPhase not listedNCT05978141

A Registry for People With T-cell Lymphoma

Sponsor: Memorial Sloan Kettering Cancer Center

St Louis, MO · +25 more sites

RecruitingPhase not listedNCT01790152

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Sponsor: Children's Oncology Group

Columbia, MO · St Louis, MO · +67 more sites

RecruitingPhase 1 / Phase 2NCT05643742

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Sponsor: CRISPR Therapeutics AG

St Louis, MO · +3 more sites

RecruitingNot applicableNCT04986657

Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

Sponsor: Washington University School of Medicine

St Louis, MO

Not yet recruitingPhase 1NCT07617363

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Sponsor: Washington University School of Medicine

St Louis, MO

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.